February 24, 2017 07:20 AM EST
R&D

Mer­ck tees up US/Eu­ro­pean ap­pli­ca­tions for leter­movir af­ter de­tail­ing PhI­II an­tivi­ral suc­cess

John Carroll

Editor & Founder

Mer­ck has un­veiled the pos­i­tive da­ta be­hind its Phase III win for its an­tivi­ral leter­movir. While it’s no panacea, the drug clear­ly out­per­formed a place­bo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times